Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Richard E. Valocik"'
Autor:
Anthony J. Pateman, John R. Toomey, Paul F. Koster, Augustin Amour, Saul Needle, Laiq Chaudry, Melanie A Abboud, Champa Patel, Angela Patikis, Cynthia L. Burns-Kurtis, Robert J. Young, Richard E. Valocik, David Brown, Ping Zhou, Chuen Chan, Nigel S. Watson
Publikováno v:
Journal of Cardiovascular Pharmacology. 52:66-71
Background: Factor Xa (FXa) has been a target of considerable interest for drug development efforts aimed at suppressing thrombosis. In this report, a new orally active, small molecule, active-site directed FXa inhibitor, GW813893, has been profiled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e4ecf88e87e341213f5fef72bbcb248
https://doi.org/10.1097/fjc.0b013e31817e9b9e
https://doi.org/10.1097/fjc.0b013e31817e9b9e
Autor:
James Samanen, Robert N. Willette, Frank C. Barone, Paul F. Koster, John R. Toomey, Richard E. Valocik
Publikováno v:
Current Drug Target -Cardiovascular & Hematological Disorders. 2:13-25
In patients with acute coronary syndromes, inhibition of platelet aggregation with parenteral alpha(IIb)/beta(III) antagonists has proven effective at preventing nonfatal myocardial infarction and repeat percutaneous coronary interventions. Paradoxic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25f5c2501ac52f82eae0a26cd6329224
https://doi.org/10.2174/1568006023337772
https://doi.org/10.2174/1568006023337772
Autor:
Paul F. Koster, Melanie A. Gabriel, Matt McVey, Eliot H. Ohlstein, Richard E. Valocik, Timothy K. Hart, Andrew A. Parsons, Frank C. Barone, John R. Toomey
Publikováno v:
Stroke. 33:578-585
Background and Purpose — Although used clinically to prevent stroke, there are few examples of anticoagulant investigations in the treatment of acute thromboembolic stroke in animal models. The treatment of thromboembolic stroke in experimental mod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e543aa4bf612155e91d644dbebcd891
https://doi.org/10.1161/hs0202.102950
https://doi.org/10.1161/hs0202.102950
Autor:
Angela S. Wong, James F. Callahan, William H. Miller, Catherine C.K. Yuan, Raul R. Calvo, Janice A. Vasko-Moser, Thomas W. Ku, Richard E. Valocik, Dennis T. Takata, Richard M. Keenan, Drake S. Eggleston, Michael F. Parker, Southall Linda Sue, S M Hwang, Paul F. Koster, William F. Huffman, Tobias Oregon Yellin, Chet Kwon, Irene N. Uzinskas, Bondinell William E, Fadia E. Ali, Dalia R. Jakas, Andrew J. Nichols, James Samanen, R. Curtis Haltiwanger, Kenneth A. Newlander
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 6:2481-2486
In an investigation of the contribution of N-1 to the binding, antiaggregatory, and oral activity in 3-oxo-1,4-benzodiazepine-2-acetic acid based GPIIb/IIIa antagonists, a series of 2-benzazepine analogs, wherein N-1 of the 1,4-benzodiazepine nucleus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ef79983c86eb17cdad500249ba3114f
https://doi.org/10.1016/0960-894x(96)00432-5
https://doi.org/10.1016/0960-894x(96)00432-5
Autor:
Robert Gagnon, Giora Z. Feuerstein, Robin Fears, Andrew J. Nichols, Robert R. Ruffolo, Richard E. Valocik, Teresa S. Sellars, Harry Ferres
Publikováno v:
Journal of Cardiovascular Pharmacology. 25:625-633
Anistreplase is a thrombolytic agent comprising a complex of streptokinase, lys-plasminogen, and a p-anisoyl group, which temporarily protects the catalytic center of the enzyme complex. Streptokinase was previously shown to reduce infarct size (IS)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7f531bd844bb0c1d2eac52406178ef3
https://doi.org/10.1097/00005344-199504000-00017
https://doi.org/10.1097/00005344-199504000-00017
Autor:
Richard E. Valocik, Arun Patel, Blackburn Michael Neal, Paul F. Koster, John R. Toomey, Giora Z. Feuerstein
Publikováno v:
Thrombosis and Haemostasis. 82:1443-1445
SummaryAn inhibitory anti-factor IX/IXa antibody (BC2) has been investigated as an anti-thrombotic agent in a rat venous thrombosis model. The treatment of rats post-injury with a single bolus dose of BC2 (3mg/kg, iv.) resulted in an ~4 fold reductio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0085bd5029f1cb12c86b14a74d14649b
https://doi.org/10.1055/s-0037-1614852
https://doi.org/10.1055/s-0037-1614852
Autor:
Joseph A. Erhardt, Richard E. Valocik, Kodandaram Pillarisetti, John R. Toomey, Cynthia L. Burns-Kurtis, Paul F. Koster, T. M. Danoff, Melanie A Abboud
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 4(9)
Summary Background: A significant need exists for new chronic oral anticoagulation therapies to replace warfarin. Previous studies have shown that β-D-xylosides, which prime glycosaminoglycan (GAG) synthesis, have antithrombin and antithrombotic act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff1fbf61e5e540d68e97ff07eb35da2e
https://pubmed.ncbi.nlm.nih.gov/16961606
https://pubmed.ncbi.nlm.nih.gov/16961606
Autor:
Giora Z. Feuerstein, Barbara L. Storer, Richard E. Valocik, Paul F. Koster, Michael N. Blackburn, John R. Toomey
Publikováno v:
Thrombosis research. 100(1)
A humanized inhibitory anti-factor IX(a) antibody (SB 249417) has been compared to enoxaparin (Lovenox) in a rat model of arterial thrombosis. Pretreatment of rats with either SB 249417 (3.0 mg/kg, i. v.) or enoxaparin (30.0 mg/kg, i.v. or s.c.) resu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eed8690b965e92fb350f9c69770d69e
https://pubmed.ncbi.nlm.nih.gov/11053619
https://pubmed.ncbi.nlm.nih.gov/11053619
Autor:
Giora Z. Feuerstein, William R. Church, Paul F. Koster, Arun Patel, Peter J. Bugelski, Andrew J. Nichols, Richard E. Valocik, John R. Toomey, Michael N. Blackburn, Audrey Baker
Publikováno v:
Arteriosclerosis, thrombosis, and vascular biology. 19(10)
Abstract —A murine antihuman factor IX monoclonal antibody (BC2) has been generated and evaluated for its capacity to prolong the activated partial thromboplastin time (aPTT) in vitro and ex vivo and to prevent arterial thrombosis in a rat model in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8f1679e111811df692bf869b2498fee
https://pubmed.ncbi.nlm.nih.gov/10521387
https://pubmed.ncbi.nlm.nih.gov/10521387
Autor:
Andrew A. Parsons, Paul F. Koster, Giora Z. Feuerstein, Robert Gagnon, Nick Tilford, Richard E. Valocik, Pravin Raval
Publikováno v:
Journal of cardiovascular pharmacology. 32(6)
The effects of frovatriptan (VML 251/SB-209509) on coronary artery function were investigated in isolated coronary arteries from beagle dogs. Low concentrations of frovatriptan produced contraction with -logEC50 7.55 +/- 0.08 (n = 11). The maximal ob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::584987fe5d6d77241a6dd55187bd1973
https://pubmed.ncbi.nlm.nih.gov/9869507
https://pubmed.ncbi.nlm.nih.gov/9869507